A significant development: Two leading biologists have left U.S. academic institutions to join China’s private Westlake University. According to a release from Westlake University on October 13, Jun Wu, formerly a professor in the Department of Molecular Biology at the University of Texas Southwestern Medical Center, joined the university full-time in September as a Chair Professor in Stem Cell Biology and Regenerative Medicine within the School of Life Sciences.
Additionally, biologist Sheng Zhong has recently joined Westlake University as a Chair Professor in the School of Medicine. Zhong’s credentials are equally impressive—undergraduate studies at Peking University, a Ph.D. from Harvard, former leadership of the NIH’s 4D Nucleome Program, founding director of the Center for Biomedical Artificial Intelligence at UCSD, and recipient of the NIH Director’s Pioneer Award. This is not a return driven by “sentimental attachment,” but rather a strategic alignment with institutional capacity.
Speaking directly, Wu noted that China has already established a competitive advantage in the field of stem cell-derived embryo models, with many of his former postdoctoral researchers returning home and achieving world-class standards. This trend is not attributable to patriotic sentiment alone, but reflects genuine advancements in China’s research ecosystem—increasing funding, advanced equipment, high talent density, and a growing scholarly environment. Indeed, Westlake University, founded by Yigong Shi, follows a “small but elite” model, with independent principal investigator (PI) systems and research conditions approaching those of top-tier institutions in the United States.
Several overseas scholars have arrived this year: Hong Qian joined in April from the University of Washington, followed by Wu and Zhong. These appointments indicate that China’s private research universities are developing their own appeal—not merely through financial incentives, but through institutional design and academic culture. For decades, the flow of Chinese talent has been one-way to the U.S.; now, a reversal is emerging. The fact that Wu, having just secured tenure in the U.S., chose to leave suggests that China’s top-level laboratories can now offer research environments and career prospects comparable to those in America. While this is not the final stage of change, it does represent a notable shift in direction.
Original source: toutiao.com/article/1879282905972864/
Disclaimer: The views expressed in this article are those of the author.